Widely respected by U.S. and African activists for her work on global AIDS, she’s also increasingly seen as playing fast and loose with COVID facts to appease President Trump.
IPERGAY scientists recommended that clinicians screen patients who request PrEP, as well as patients who are already using it, for a number of key HCV risk factors.
An in-depth update on what we know about HCV risk, symptoms, screening, outcomes, and treatment (including financial barriers).
A new study puts numbers to increasingly divergent trends in liver-related deaths vs. injection-related deaths in recent years, highlighting both the success of modern HCV treatment and the devastating effects of the opioid crisis.
Six thousand HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.
TheBodyPro is covering all the latest in HIV science at the biggest annual gathering of HIV researchers in the U.S. Here's a preview of what's to come.
In clinical trials called Sword 1 and Sword 2, researchers testing a combination of dolutegravir/rilpivirine (Juluca) found it to be effective and tolerable.
With Only 15% of Diagnosed HCV Patients Receiving Treatment, the Non-Profit I-MAK Hopes to Shift the National Conversation on Drug Pricing
The Initiative for Medicines, Access and Knowledge, Inc. (I-MAK) argues that the high price of hepatitis C cure medicines places them out of reach for most people.
The ongoing struggle to enable access to sofosbuvir globally at affordable prices continues with several new developments.
An international group of treatment activists interrupted a session at AIDS 2014 just as Gregg H. Alton, a top official at Gilead Sciences, was about to speak regarding the challenges of expanding global access to the new generation of hepatitis C dr...